215 related articles for article (PubMed ID: 26619158)
41. HSA coated MnO nanoparticles with prominent MRI contrast for tumor imaging.
Huang J; Xie J; Chen K; Bu L; Lee S; Cheng Z; Li X; Chen X
Chem Commun (Camb); 2010 Sep; 46(36):6684-6. PubMed ID: 20730157
[TBL] [Abstract][Full Text] [Related]
42. Cell uptake and intracellular fate of phospholipidic manganese-based nanoparticles.
Costanzo M; Scolaro L; Berlier G; Marengo A; Grecchi S; Zancanaro C; Malatesta M; Arpicco S
Int J Pharm; 2016 Jul; 508(1-2):83-91. PubMed ID: 27173822
[TBL] [Abstract][Full Text] [Related]
43. Synthesizing and staining manganese oxide nanoparticles for cytotoxicity and cellular uptake investigation.
Omid H; Oghabian MA; Ahmadi R; Shahbazi N; Hosseini HR; Shanehsazzadeh S; Zangeneh RN
Biochim Biophys Acta; 2014 Jan; 1840(1):428-33. PubMed ID: 24112973
[TBL] [Abstract][Full Text] [Related]
44. Tunable Performance of Manganese Oxide Nanostructures as MRI Contrast Agents.
Bañobre-López M; García-Hevia L; Cerqueira MF; Rivadulla F; Gallo J
Chemistry; 2018 Jan; 24(6):1295-1303. PubMed ID: 29178467
[TBL] [Abstract][Full Text] [Related]
45. Convertible MRI contrast: Sensing the delivery and release of anti-glioma nano-drugs.
Zhang L; Zhang Z; Mason RP; Sarkaria JN; Zhao D
Sci Rep; 2015 May; 5():9874. PubMed ID: 25962872
[TBL] [Abstract][Full Text] [Related]
46. MnO nanoparticles with unique excitation-dependent fluorescence for multicolor cellular imaging and MR imaging of brain glioma.
Lai J; Wang T; Wang H; Shi F; Gu W; Ye L
Mikrochim Acta; 2018 Apr; 185(4):244. PubMed ID: 29610993
[TBL] [Abstract][Full Text] [Related]
47. Engineering manganese ferrite shell on iron oxide nanoparticles for enhanced T
Li M; Bao J; Zeng J; Huo L; Shan X; Cheng X; Qiu D; Miao W; Zhu X; Huang G; Ni K; Zhao Z
J Colloid Interface Sci; 2022 Nov; 626():364-373. PubMed ID: 35797871
[TBL] [Abstract][Full Text] [Related]
48. Tumor-targeted responsive nanoparticle-based systems for magnetic resonance imaging and therapy.
Savla R; Garbuzenko OB; Chen S; Rodriguez-Rodriguez L; Minko T
Pharm Res; 2014 Dec; 31(12):3487-502. PubMed ID: 24919932
[TBL] [Abstract][Full Text] [Related]
49. Synthesis of Ferromagnetic Fe0.6 Mn0.4 O Nanoflowers as a New Class of Magnetic Theranostic Platform for In Vivo T1 -T2 Dual-Mode Magnetic Resonance Imaging and Magnetic Hyperthermia Therapy.
Liu XL; Ng CT; Chandrasekharan P; Yang HT; Zhao LY; Peng E; Lv YB; Xiao W; Fang J; Yi JB; Zhang H; Chuang KH; Bay BH; Ding J; Fan HM
Adv Healthc Mater; 2016 Aug; 5(16):2092-104. PubMed ID: 27297640
[TBL] [Abstract][Full Text] [Related]
50. A simple mathematical model for manganese oxide-coated montmorillonite as a catalyst for water oxidation: from nano to macro sized manganese oxide.
Najafpour MM; Nemati Moghaddam A; Sakha Y
Dalton Trans; 2013 Aug; 42(30):11012-20. PubMed ID: 23797618
[TBL] [Abstract][Full Text] [Related]
51. Manganese oxide-based multifunctionalized mesoporous silica nanoparticles for pH-responsive MRI, ultrasonography and circumvention of MDR in cancer cells.
Chen Y; Yin Q; Ji X; Zhang S; Chen H; Zheng Y; Sun Y; Qu H; Wang Z; Li Y; Wang X; Zhang K; Zhang L; Shi J
Biomaterials; 2012 Oct; 33(29):7126-37. PubMed ID: 22789722
[TBL] [Abstract][Full Text] [Related]
52. PSA targeted dual-modality manganese oxide-mesoporous silica nanoparticles for prostate cancer imaging.
Du D; Fu HJ; Ren WW; Li XL; Guo LH
Biomed Pharmacother; 2020 Jan; 121():109614. PubMed ID: 31731188
[TBL] [Abstract][Full Text] [Related]
53. Development of PEGylated KMnF3 nanoparticles as a T1-weighted contrast agent: chemical synthesis, in vivo brain MR imaging, and accounting for high relaxivity.
Liu ZJ; Song XX; Tang Q
Nanoscale; 2013 Jun; 5(11):5073-9. PubMed ID: 23640287
[TBL] [Abstract][Full Text] [Related]
54. MnO-labeled cells: positive contrast enhancement in MRI.
Létourneau M; Tremblay M; Faucher L; Rojas D; Chevallier P; Gossuin Y; Lagueux J; Fortin MA
J Phys Chem B; 2012 Nov; 116(44):13228-38. PubMed ID: 23030472
[TBL] [Abstract][Full Text] [Related]
55. Tuning the size and composition of manganese oxide nanoparticles through varying temperature ramp and aging time.
Martinez de la Torre C; Grossman JH; Bobko AA; Bennewitz MF
PLoS One; 2020; 15(9):e0239034. PubMed ID: 32946514
[TBL] [Abstract][Full Text] [Related]
56. Mn(II)-containing coordination nanoparticles as highly efficient T(1) contrast agents for magnetic resonance imaging.
Paul G; Prado Y; Dia N; Rivière E; Laurent S; Roch M; Elst LV; Muller RN; Sancey L; Perriat P; Tillement O; Mallah T; Catala L
Chem Commun (Camb); 2014 Jun; 50(51):6740-3. PubMed ID: 24829060
[TBL] [Abstract][Full Text] [Related]
57. Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging.
Bae KH; Lee K; Lee J; Lee IS; Lee JH; Park TG
J Control Release; 2011 Nov; 152 Suppl 1():e133-4. PubMed ID: 22195802
[No Abstract] [Full Text] [Related]
58. Tunable T1 and T2 contrast abilities of manganese-engineered iron oxide nanoparticles through size control.
Huang G; Li H; Chen J; Zhao Z; Yang L; Chi X; Chen Z; Wang X; Gao J
Nanoscale; 2014 Sep; 6(17):10404-12. PubMed ID: 25079966
[TBL] [Abstract][Full Text] [Related]
59. Manganese oxide and docetaxel co-loaded fluorescent polymer nanoparticles for dual modal imaging and chemotherapy of breast cancer.
Abbasi AZ; Prasad P; Cai P; He C; Foltz WD; Amini MA; Gordijo CR; Rauth AM; Wu XY
J Control Release; 2015 Jul; 209():186-96. PubMed ID: 25908171
[TBL] [Abstract][Full Text] [Related]
60. Improving the sensitivity of
Yang L; Wang L; Huang G; Zhang X; Chen L; Li A; Gao J; Zhou Z; Su L; Yang H; Song J
Theranostics; 2021; 11(14):6966-6982. PubMed ID: 34093865
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
